CDL Nuclear Technologies published a recent longitudinal study using F18 FDG-PET/MRI findings that androgen deprivation therapy (ADT) was associated with progressive arterial inflammation in men with prostate cancer.

CDL Nuclear Technologies partners with cardiology practices and health systems to implement and expand Cardiac PET/CT programs through scalable, fully integrated solutions. For more than 30 years, CDL has advanced access to cardiac imaging by supporting programs from early adoption through long-term growth, helping reduce barriers to entry while delivering predictable, scalable models. CDL is the #1 provider of custom Cardiac PET and PET/CT suite buildouts in the US, supporting more than 200 Cardiac PET and PET/CT labs nationwide. The CDL Cardiac PET 360 Approach CDL’s Cardiac PET 360 model provides a flexible, scalable journey that evolves with each organization’s clinical needs, operational infrastructure, and patient volumes. Through scalable deployment pathways, including on-demand mobile Rubidium-82, Flurpiridaz F-18 capabilities, mobile and fixed PET/CT solutions, and custom PET/CT suites, healthcare organizations can offer advanced cardiac imaging with clarity and confidence.   By combining infrastructure, clinical expertise, and flexible delivery models, CDL helps healthcare providers expand access to advanced cardiac imaging, bringing high-quality cardiac care closer to the patients who need it.